Gastrointestinal mucus generally exists as two layers, a basal 'unstirred' or 'firmly adherent' layer and a luminal 'stirred' or 'sloppy' layer [74–76] ; however, most of the cited references report ...

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the betacoronavirus responsible for the coronavirus disease-19 (COVID-19) pandemic, has caused over 111 million infections globally and ...

The human body has built-in protections to keep pathogens out. That sneezing fit or stuffy nose when you have a cold? That’s your body leveraging mucosal linings in your respiratory system to expel ...

When the COVID-19 pandemic first started, no effective anti-viral drugs were available to fight the disease. However, in record time, so-called monoclonal antibodies were developed as a lifesaving ...

This is a preview. Log in through your library . Abstract Tuberculosis (TB) claims 1.5 million lives per year. This situation is largely due to the low efficacy of the only licensed TB vaccine, ...

In a recent study posted to the bioRxiv* preprint server, researchers describe a mucosal vector vaccine for targeting dendritic cells. Study: A synthetic delivery vector for mucosal vaccination. Image ...

Mucosal Vaccine Delivery Systems: The Future of Immunization (Part 1) is a new release from Bentham Science that delivers a comprehensive exploration of mucosal immunization strategies, offering fresh ...

SAN DIEGO & COPENHAGEN, Denmark--(BUSINESS WIRE)--AFYX Therapeutics (“AFYX”), a clinical-stage biopharmaceutical company developing innovative approaches to treat mucosal diseases, announced results ...

While rapid identification of pathogens, novel therapeutic interventions, and passive immunization have critical roles in disease control, none can substitute for pre-existing protective immunity.

The mucosal route plays an important role in nanoscale delivery. The nanoscale systems have to penetrate or diffuse through the mucosal membrane to reach the epithelium as depicted in Figure 3A & B.